Naim Maalouf is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5323 Harry Hines Blvd
Dallas, TX 753907201
Telephone
214-648-2954Registry record last updated 24 Jun 2013.
Clinical trials
- Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones
Sponsor: University of Texas Southwestern Medical Center
- Treatment for Calcium Phosphate Kidney Stone Disease
Sponsor: University of Texas Southwestern Medical Center
- Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
Sponsor: University of Texas Southwestern Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
35.7%Parathyroid Hormone Analog26%Teriparatide54%Forteo46%Part D<11 patientsl-Thyroxine9.7%Levothyroxine Sodium59%Synthroid41%Part D<11 patientsMetabolism & gastrointestinal
33.1%Metabolic Alkalinizer17.1%Potassium Citrate Er100%Part D≥19 patientsVitamin D3 Analog7.1%Calcitriol100%Part D<11 patients+ 2 more classes in this area
Cardiovascular
31.1%Thiazide diuretic14.6%Hydrochlorothiazide100%Part D≥14 patientsThiazide-like diuretic11.7%Indapamide71%Chlorthalidone29%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2005–2026 per NIH RePORTER. The latest:
- Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones
Ut Southwestern Medical Center
FY2026$471,750R01DK136684 - Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones
Ut Southwestern Medical Center
FY2025$471,750R01DK136684 - Fluid Therapy and Stent Management in Nephrolithiasis, USDRN extension
Ut Southwestern Medical Center
FY2024$479,998U01DK110994
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”